A Phase Ia/Ib Open Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors.
| Předmět: | |
|---|---|
| Zdroj: | Cancer Vaccine Week; 6/8/2023, p21-21, 1p |
| Abstrakt: | Patients with advanced metastatic malignancies who have failed first-line, or second-line, or third-line, or fourth-line standard therapies, or who not appropriate for standard treatment, cannot tolerate chemotherapy, or do not have effective standard therapies. [Extracted from the article] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|